Comparing treatments before surgery for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study compares a new drug (JS004) added to an immunotherapy and chemotherapy combination versus the usual immunotherapy plus chemotherapy or chemotherapy alone. It aims to see if adding this new drug can shrink breast cancer more effectively before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have a new diagnosis of stage II or stage III breast cancer that has not spread to other parts of the body.
- Your cancer is triple-negative breast cancer, meaning it does not have estrogen, progesterone, or HER2 receptors.
- You have not had chemotherapy, radiation, or surgery for this breast cancer yet.
- You are generally healthy enough for treatment, with good heart, liver, and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy, before surgery, can improve treatment for early triple-negative breast cancer. It compares two chemotherapy approaches—one with anthracyclines and one without—to see which works better when combined with toripalimab.
This trial studies a new drug called QL1706 (an immunotherapy that helps your immune system fight cancer) combined with standard chemotherapy before surgery. The goal is to see if this combination can shrink or eliminate the tumor more effectively in early-stage triple-negative breast cancer, potentially improving your long-term outcome.
This trial tests whether giving chemotherapy plus the immunotherapy drug toripalimab before surgery can improve outcomes for women with early-stage triple-negative breast cancer that tests positive for PD-L1.
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
This trial looks at whether adding immunotherapy to chemotherapy before surgery helps people with triple-negative breast cancer. It compares different treatment approaches to see which works better.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.